Počet záznamů: 1
Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula
- 1.
SYSNO ASEP 0568956 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Endothelin type A receptor blockade increases renoprotection in congestive heart failure combined with chronic kidney disease: Studies in 5/6 nephrectomized rats with aorto-caval fistula Tvůrce(i) Kala, P. (CZ)
Vaňourková, Z. (CZ)
Škaroupková, P. (CZ)
Kompanowska - Jezierska, E. (PL)
Sadowski, J. (PL)
Walkowska, A. (PL)
Veselka, J. (CZ)
Táborský, M. (CZ)
Maxová, H. (CZ)
Vaněčková, Ivana (FGU-C) RID, ORCID
Červenka, L. (CZ)Celkový počet autorů 11 Číslo článku 114157 Zdroj.dok. Biomedicine & Pharmacotherapy. - : Elsevier - ISSN 0753-3322
Roč. 158, February (2023)Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. FR - Francie Klíč. slova congestive heart failure ; chronic kidney disease ; endothelin system ; endothelin receptor type A ; aorto-caval fistula ; 5/6 nephrectomy Obor OECD Cardiac and Cardiovascular systems CEP LX22NPO5104 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 000916209900001 EID SCOPUS 85145296028 DOI 10.1016/j.biopha.2022.114157 Anotace Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient's prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antagonist to the angiotensin-converting enzyme inhibitor (ACEi) will bring additional beneficial effects in experimental rats.Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) and CHF was elicited by volume overload achieved by creation of aorto-caval fistula (ACF). The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF creation.Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, however, the difference between the combination and either single treatment regimen was not significant. The combined treatment exerted best renoprotection, causing additional reduction in albuminuria and reducing renal glomerular and tubulointerstitial injury as compared with ACE inhibition alone.Conclusions: Our results show that treatment with ETA receptor antagonist attenuates the CKD-and CHF-related mortality, and addition of ETA receptor antagonist to the standard blockade of RAS by ACEi exhibits additional renoprotective actions. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2024 Elektronická adresa https://doi.org/10.1016/j.biopha.2022.114157
Počet záznamů: 1